Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis; D001549:Benzamides; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004730:Endothelium, Vascular / Q000473:pathology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D051379:Mice; D008819:Mice, Nude; D008856:Microscopy, Fluorescence; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000473:pathology*; D017239:Paclitaxel / Q000494:pharmacology; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000096:biosynthesis; D011743:Pyrimidines / Q000494:pharmacology; D017479:Receptors, Platelet-Derived Growth Factor / Q000096:biosynthesis / Q000737:chemistry* / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor; D017239:Paclitaxel